Mostrar el registro sencillo del ítem

Bone Health in Children and Youth with Cystic Fibrosis: A Systematic Review and Meta-Analysis of Matched Cohort Studies

dc.contributor.authorUbago-Guisado E.
dc.contributor.authorCavero-Redondo I.
dc.contributor.authorAlvarez-Bueno C.
dc.contributor.authorVlachopoulos D.
dc.contributor.authorMartínez-Vizcaíno V.
dc.contributor.authorGracia-Marco L.
dc.date.accessioned2020-09-02T22:29:26Z
dc.date.available2020-09-02T22:29:26Z
dc.date.issued2019
dc.identifier10.1016/j.jpeds.2019.07.073
dc.identifier.citation215, , 178-186.e16
dc.identifier.issn00223476
dc.identifier.urihttps://hdl.handle.net/20.500.12728/6451
dc.descriptionObjective: To assess the evidence regarding the differences in areal bone mineral density (aBMD) between children and adolescents with cystic fibrosis (CF) compared with their healthy peers, based on data from longitudinal studies. Study design: We searched MEDLINE, SPORTDiscus, the Cochrane Library, PEDro (Physiotherapy Evidence Database), and Embase databases. Observational studies addressing the change of aBMD in children with CF and healthy children and adolescents were eligible. The DerSimonian and Laird method was used to compute pooled estimates of effect sizes (ES) and 95% CIs for the change of whole body (WB), lumbar spine (LS), and femoral neck (FN) aBMD. Results: Six studies with participants with CF and 26 studies with healthy participants were included in the systematic review and meta-analysis. For the analysis in children with CF, the pooled ES for the change of WB aBMD was 0.29 (95% CI –0.15 to 0.74), for the change of LS aBMD was 0.13 (95% CI –0.16 to 0.41), and for the change of FN aBMD was 0.09 (95% CI –0.39 to 0.57). For the analysis in healthy children, the pooled ES for the change of WB aBMD was 0.37 (95% CI 0.26-0.49), for the change of LS aBMD was 0.13 (95% CI –0.16 to 0.41), and for the change of FN aBMD was 0.52 (95% CI 0.19-0.85). Conclusions: aBMD development might not differ between children and adolescents with CF receiving medical care compared with their healthy peers. Further longitudinal studies in a CF population during growth and development are required to confirm our findings. © 2019 Elsevier Inc.
dc.language.isoen
dc.publisherMosby Inc.
dc.subjectadolescence
dc.subjectbone mass
dc.subjectdensitometry
dc.subjectpediatric
dc.subjectyouth
dc.subjectadolescent
dc.subjectArticle
dc.subjectbone density
dc.subjectchild
dc.subjectcystic fibrosis
dc.subjectdual energy X ray absorptiometry
dc.subjectfemoral neck
dc.subjecthuman
dc.subjectlumbar spine
dc.subjectpriority journal
dc.subjectquality assessment tool
dc.subjectrandomized controlled trial (topic)
dc.subjectsystematic review
dc.subjectbone density
dc.subjectcystic fibrosis
dc.subjectlumbar vertebra
dc.subjectmeta analysis
dc.subjectpathophysiology
dc.subjectphoton absorptiometry
dc.subjectphysiology
dc.subjectAbsorptiometry, Photon
dc.subjectBone Density
dc.subjectChild
dc.subjectCystic Fibrosis
dc.subjectFemur Neck
dc.subjectHumans
dc.subjectLumbar Vertebrae
dc.titleBone Health in Children and Youth with Cystic Fibrosis: A Systematic Review and Meta-Analysis of Matched Cohort Studies
dc.typeArticle


Ficheros en el ítem

Thumbnail
Nombre:
item_2-s2.0-85071932524.pdf
Tamaño:
3.316Kb
Formato:
PDF
Ver/

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem